CONTACT
+91 80 2808 2808
info@biocon.com

Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA

  • Posted by: BIOCON

Bengaluru, India, June 23, 2018

“The Company confirms that Biocon has received an Establishment Inspection Report (EIR) from the USFDA for its Sterile Drug Product manufacturing facility in Bangalore, following the USFDA pre-approval inspection of this facility in April/ May 2018. EIR notifies that the inspection stands closed. Biocon is committed to global standards of quality and compliance.”

– Company Spokesperson

Author: BIOCON
Share
Previous Next
Close
Test Caption
Test Description goes like this